Argenx SE Files 6-K Report
Ticker: ARGX · Form: 6-K · Filed: Oct 30, 2025 · CIK: 1697862
Sentiment: neutral
Topics: regulatory-filing, 6-K, foreign-private-issuer
TL;DR
Argenx SE filed their Q3 2025 6-K, check it for updates.
AI Summary
Argenx SE filed a Form 6-K on October 30, 2025, reporting for the period ending September 30, 2025. The filing is a report of a foreign private issuer and includes information related to their business operations and financial reporting.
Why It Matters
This filing provides an update on Argenx SE's activities as a foreign private issuer, which is important for investors tracking the company's regulatory disclosures.
Risk Assessment
Risk Level: low — This is a routine regulatory filing for a foreign private issuer and does not contain significant new financial or operational information that would inherently increase risk.
Key Players & Entities
- ARGENX SE (company) — Filer of the report
- 001-38097 (company) — SEC File Number
- 20251030 (date) — Filing date
- 20250930 (date) — Period of report
FAQ
What type of company is Argenx SE?
Argenx SE is a company in the Biological Products sector, specifically not including diagnostic substances, with SIC code 2836.
What is the filing date of this Form 6-K?
The filing date is October 30, 2025.
What period does this Form 6-K report cover?
This Form 6-K reports for the period ending September 30, 2025.
Where is Argenx SE's principal executive office located?
Argenx SE's principal executive offices are located at Laarderhoogtweg 25, 1101 EB Amsterdam, the Netherlands.
Is Argenx SE required to file annual reports under Form 20-F?
Yes, Argenx SE indicates it files or will file annual reports under cover of Form 20-F.
Filing Stats: 302 words · 1 min read · ~1 pages · Grade level 12.9 · Accepted 2025-10-30 08:04:37
Filing Documents
- a01coverpageforsecfilingq3.htm (6-K) — 18KB
- a02earningspressreleaseq3.htm (EX-99.1) — 141KB
- argxq3investorpresentati.htm (EX-99.2) — 18KB
- argenx_logoxrgba.jpg (GRAPHIC) — 110KB
- argxq3investorpresentati001.jpg (GRAPHIC) — 101KB
- argxq3investorpresentati002.jpg (GRAPHIC) — 280KB
- argxq3investorpresentati003.jpg (GRAPHIC) — 78KB
- argxq3investorpresentati004.jpg (GRAPHIC) — 111KB
- argxq3investorpresentati005.jpg (GRAPHIC) — 113KB
- argxq3investorpresentati006.jpg (GRAPHIC) — 107KB
- argxq3investorpresentati007.jpg (GRAPHIC) — 96KB
- argxq3investorpresentati008.jpg (GRAPHIC) — 102KB
- argxq3investorpresentati009.jpg (GRAPHIC) — 105KB
- argxq3investorpresentati010.jpg (GRAPHIC) — 93KB
- argxq3investorpresentati011.jpg (GRAPHIC) — 88KB
- argxq3investorpresentati012.jpg (GRAPHIC) — 88KB
- argxq3investorpresentati013.jpg (GRAPHIC) — 124KB
- argxq3investorpresentati014.jpg (GRAPHIC) — 133KB
- argxq3investorpresentati015.jpg (GRAPHIC) — 123KB
- 0001697862-25-000059.txt ( ) — 2719KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. ARGENX SE Date October 30, 2025 By s Hemamalini (Malini) Moorthy Hemamalini (Malini) Moorthy General Counsel